The treatment group will have faecal microbiota transplantation performed using stool from a healthy human donor

The placebo group will have autologous faecal microbiota transplantation performed.

Irritable Bowel Syndrome

Faecal microbiota transplantation

Alimentary Pharmabiotic Centre, University College Cork

Faecal Microbiota Transplantation in Irritable Bowel Syndrome

Randomised Placebo Controlled Trial of Faecal Microbiota Transplantation in Irritable Bowel Syndrome

This assessment will be obtained by defining the response (Yes or No) to the following question.
"Please consider how you felt in the past week in regard to your IBS, in particular your overall well-being, and symptoms of abdominal discomfort or pain, bloating or distension and altered bowel habit .Compared to the way you usually felt before the beginning of the trial, have you had adequate relief of your IBS-symptoms?"

The primary symptoms of IBS will be scored on a six point Likert scale at baseline, week 4 and at end of study. The following symptoms will be assessed and recorded: abdominal pain/discomfort, bloating/distension, sense of incomplete evacuation, straining at stool, urgency of bowel movement, passage of gas and mucus, bowel habit satisfaction. Each symptom will be assessed using a 6-point scale, where 0 = none to 5 = very severe. Bowel habit satisfaction will be assessed using a 6-point scale where 0 = very satisfied and 5 = very dissatisfied. Overall assessment of IBS symptoms will be also be scored on a 6 - point scale. An IBS composite score(15 point score) representing the sum of individual scores for abdominal pain/discomfort, bloating/distension, and bowel movement difficulty (straining at stool or urgency of bowel movement) will be calculated.

At baseline and at the end of the study each subject will complete an IBS-specific quality of life questionnaire (IBS-QOL)

At baseline and at the end of the study each subject will complete the Hospital Anxiety and Depression (HAD) Scale.

Patients will be monitored throughout the study period and they will be recorded as per the The Consolidated Standards of Reporting Trials (CONSORT) criteria

We will characterise all participants' microbiota composition at baseline and at the end of study to determine if there is a subgroup of patient/donor combinations, based on their microbiota composition, in whom a positive response to FMT was obtained. This would be very valuable for future optimization of a positive primary outcome.

Professor Fergus Shanahan

Professor and Chair Department of Medicine and Director Alimentary Pharmabiotic Centre, University College Cork

University College Cork

Group A will receive fish oil capsules, containing n3-Fatty Acids, at a dose of 4g/day. Each 1g capsule will contain 465mg of EPA and 375 mg of DHA.

Group B will receive corn oil in the capsules at the same dose as Group A. The corn oil capsules will appear identical in size and color to the fish oil capsules.

Non-Alcoholic Fatty Liver Disease

Fish Oil Supplementation

Placebo Supplementation

Irving Clinical Research Center (GCRC) at Columbia University Medical Center

Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study

Fish Oil for the Treatment of Nonalcoholic Fatty Liver Disease in Children

To evaluate whether young adults with obesity related NAFLD will normalize their elevated liver enzyme levels with supplements of fish oil (n-3 FA containing eicosapentanoic acid and decosahexaenoic acid).

To evaluate whether young adults with obesity-related NAFLD and associated dyslipidemia will normalize their plasma lipid levels after fish oil supplementation.
To evaluate whether young adults with obesity related NAFLD and insulin resistance will attenuate their insulin resistance (as measured by insulin levels and estimation of HOMA-R) after fish oil supplementation.

hepatitis a/rasvumus

Faecal Microbiota Transplantation in Irritable Bowel Syndrome

Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus